Welcome to our dedicated page for Medifast news (Ticker: MED), a resource for investors and traders seeking the latest updates and insights on Medifast stock.
Medifast Inc (MED) provides investors and stakeholders with centralized access to official company announcements and market-moving developments. This resource aggregates all press releases, financial disclosures, and strategic updates from the clinical nutrition leader known for its OPTAVIA® coaching programs and evidence-based weight management solutions.
Users will find chronological updates covering earnings reports, product innovations, leadership changes, and operational milestones. The curated collection serves as both historical record and strategic tool for tracking MED's position in the $250B+ global wellness industry.
Key content categories include quarterly financial results, clinical study publications, partnership announcements, and regulatory filings. All materials are sourced directly from Medifast's investor relations team to ensure accuracy and timeliness.
Bookmark this page for streamlined monitoring of MED's business trajectory, with updates organized to highlight material developments affecting long-term growth in the health solutions sector.
Medifast reported challenging Q1 2025 results with revenue declining 33.8% to $115.7 million. The health and wellness company's OPTAVIA program saw active earning coaches decrease 32.8% to 25,400, compared to 37,800 in Q1 2024.
Key financial highlights:
- Net loss of $0.8 million ($0.07 per share)
- Revenue per active coach at $4,556
- Gross profit down 33.8% to $84.2 million
- Strong balance sheet with $164.6 million in cash and no debt
CEO Dan Chard emphasized that 83% of people seeking weight loss lack confidence in maintaining long-term health improvements. The company is focusing on revitalizing its coach and customer base through enhanced tools and new products. For Q2 2025, Medifast expects revenue between $85-105 million with projected loss per share of $0.00 to $0.55.
Medifast (NYSE: MED), the company behind the OPTAVIA® health and wellness lifestyle solution, has scheduled its first quarter 2025 financial results announcement for Monday, April 28, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET featuring Chairman and CEO Dan Chard and CFO Jim Maloney. The call will be accessible via live webcast on Medifast's Investor Relations website and will remain archived through July 28, 2025.
Telephone participants can join by dialing (201) 389-0879, with playback available from 8:30 p.m. ET on April 28 through May 5, 2025, using access code 13752614.
Medifast (NYSE: MED) reported Q4 2024 financial results with revenue of $119.0 million, down 37.7% from Q4 2023, primarily due to a 34.1% decrease in active OPTAVIA coaches to 27,100. Revenue per active coach declined 5.5% to $4,391.
Q4 net income was $0.8 million ($0.07 per share), compared to $6.0 million ($0.55 per share) in Q4 2023. Full-year 2024 revenue decreased 43.8% to $602.5 million, with net income of $2.1 million ($0.19 per share).
The company maintains a strong balance sheet with $162.3 million in cash and investments with no debt. For Q1 2025, Medifast expects revenue between $100-120 million and EPS ranging from a loss of $0.50 to $0.00 per share.
Medifast (NYSE: MED), the health and wellness company behind the OPTAVIA® lifestyle solution, has scheduled its fourth quarter and full year 2024 financial results announcement for Tuesday, February 18, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET on the same day, featuring Chairman and CEO Dan Chard and CFO Jim Maloney. The call will be broadcast live on Medifast's Investor Relations website and will remain archived through May 18, 2025. Telephone participants can dial (201) 389-0879 to join, with a playback available from 8:30 p.m. ET through February 25, 2025, accessible at (412) 317-6671 with access code 13751326.
Medifast (NYSE:MED) has launched OPTAVIA ASCEND, a new high-protein product line featuring mini meals and daily nutrient packs. The products are part of two science-backed nutrition plans targeting GLP-1 medication users and individuals seeking weight maintenance support.
The launch addresses critical challenges in the weight management market, particularly the fact that two-thirds of weight lost on GLP-1 medications is typically regained within 12 months of stopping treatment. Additionally, muscle loss on these medications can equal up to a decade of natural muscle loss within 12-18 months.
OPTAVIA ASCEND combines high-protein products with personalized coaching support and builds on Medifast's existing collaboration with LifeMD for GLP-1 medication access. The products are designed to provide essential nutrients promoting muscle, digestive, and bone health while supporting long-term weight management success through proper nutrition and lifestyle habits.
Medifast (NYSE: MED) released findings from a recent independent survey of 2,000 U.S. adults trying to lose weight, revealing key insights about weight loss medications and lifestyle changes. The survey, conducted by Talker Research, shows that 65% of respondents believe weight loss medications are more effective when combined with lifestyle changes, while 45% agree that medications alone won't achieve long-term goals.
Notable findings include: 73% would commit to healthy eating and 72% to regular exercise, even if weight loss medications were available. 58% wished for more support in their weight loss journey and would consider a medically supported program with personalized meal plans and support groups.
Studies indicate that FDA-approved GLP-1 medications combined with lifestyle modification programs like OPTAVIA may help achieve an average 15% body weight reduction. Medifast's approach incorporates both medication support and coaching for comprehensive weight management.
Medifast (NYSE: MED) reported Q3 2024 financial results with revenue of $140.2 million, down 40.6% from $235.9 million in Q3 2023. The company had 30,000 active earning OPTAVIA coaches, a 36.3% decrease from 47,100 in the previous year. Net income was $1.1 million ($0.10 per diluted share), compared to $23.1 million ($2.12 per diluted share) in Q3 2023. The company maintains a strong balance sheet with $170.0 million in cash and no debt. For Q4 2024, Medifast expects revenue between $100-120 million and projects a diluted loss per share of $0.10 to $0.65.
Medifast (NYSE: MED), the health and wellness company behind the OPTAVIA® lifestyle solution, has announced it will release its third quarter 2024 financial results on Monday, November 4, 2024, after market close. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results.
Key participants in the call will include Dan Chard, Chairman and CEO, and Jim Maloney, CFO. The call will be broadcast live on Medifast's Investor Relations website and archived for access until February 4, 2025. Telephone access is available by dialing (201) 389-0879, with a playback option available from 8:30 p.m. ET, November 4, through November 11, 2024, using access code 13749320.
Medifast (NYSE: MED) reported Q2 2024 financial results, showing a 43.1% decrease in revenue to $168.6 million. The company experienced a net loss of $8.2 million, or $0.75 per diluted share. Key metrics include:
- Revenue per active earning Coach: $4,972
- Independent active earning OPTAVIA Coaches: 33,900
- Non-GAAP adjusted net income: $10.1 million
- Non-GAAP adjusted EPS: $0.92
- Cash and equivalents: $163.5 million with zero debt
Medifast is transforming its business for long-term growth, focusing on new customer acquisition and expanding its health and wellness offerings. The company's outlook for Q3 2024 projects revenue between $125-$145 million and a diluted loss per share of $0.05 to $0.70.
Medifast (NYSE: MED), the health and wellness company behind the OPTAVIA® lifestyle solution, has announced it will release its second quarter 2024 financial results on Monday, August 5, 2024, after market close. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results, featuring Dan Chard, Chairman and CEO, and Jim Maloney, CFO.
The call will be broadcast live on Medifast's Investor Relations website and archived until November 5, 2024. Listeners can join via telephone by dialing (201) 389-0879. A telephonic playback will be available from 8:30 p.m. ET, August 5, through August 12, 2024, accessible by dialing (412) 317-6671 with access code 13747501.
FAQ
What is the current stock price of Medifast (MED)?
What is the market cap of Medifast (MED)?
